Journal
EMERGING MICROBES & INFECTIONS
Volume 8, Issue 1, Pages 516-530Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/22221751.2019.1597644
Keywords
Coronavirus; MERS; antibodies; spike protein
Categories
Funding
- IMI-ZAPI (Zoonotic Anticipation and Preparedness Initiative (ZAPI) project)
- IMI-ZAPI (Innovative Medicines Initiative (IMI)) [115760]
- IMI
- European Commission
- Ministry of Science and Innovation of Spain [BIO2016-75549-R]
- NIH [2PO1AIO6O699]
- Center for Scientific Review, China Scholarship Council
Ask authors/readers for more resources
The Middle-East respiratory syndrome coronavirus (MERS-CoV) is a zoonotic virus that causes severe and often fatal respiratory disease in humans. Efforts to develop antibody-based therapies have focused on neutralizing antibodies that target the receptor binding domain of the viral spike protein thereby blocking receptor binding. Here, we developed a set of human monoclonal antibodies that target functionally distinct domains of the MERS-CoV spike protein. These antibodies belong to six distinct epitope groups and interfere with the three critical entry functions of the MERS-CoV spike protein: sialic acid binding, receptor binding and membrane fusion. Passive immunization with potently as well as with poorly neutralizing antibodies protected mice from lethal MERS-CoV challenge. Collectively, these antibodies offer new ways to gain humoral protection in humans against the emerging MERS-CoV by targeting different spike protein epitopes and functions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available